ALOGLIPTIN BENZOATE - CAS 850649-62-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
ALOGLIPTIN BENZOATE
Catalog Number:
850649-62-6
CAS Number:
850649-62-6
Description:
Alogliptin benzoate(SYR 322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
COA:
Inquire
MSDS:
Inquire
Targets:
DPP4
Chemical Structure
CAS 850649-62-6 ALOGLIPTIN BENZOATE

Related DPP4 Products


CAS 852329-66-9 Dutogliptin

Dutogliptin
(CAS: 852329-66-9)

Dutogliptin is a selective and orally active DPP4 inhibitor. It can improve glycaemic control in patients with type 2 diabetes. But phase III clinical trials fo...

CAS 850649-61-5 Alogliptin

Alogliptin
(CAS: 850649-61-5)

Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.

CAS 1226781-44-7 Omarigliptin

Omarigliptin
(CAS: 1226781-44-7)

Omarigliptin is a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor to be used as treatment for type 2 diabetes.

ASP-8497
(CAS: 651055-26-4)

ASP8497 is a long-acting and potent DPP-IV inhibitor. It improves glucose tolerance through glucose-dependent insulinotropic action via elevation of the GLP-1 l...

CAS 668270-12-0 Linagliptin

Linagliptin
(CAS: 668270-12-0)

A novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.

CAS 945667-22-1 Saxagliptin hydrate

Saxagliptin hydrate
(CAS: 945667-22-1)

Saxagliptin hydrate is a selective and reversible DPP4 inhibitor. It demonstrates greater specificity for DPP4 than for either the DPP8 or DPP9 enzymes. It redu...

CAS 361442-04-8 Saxagliptin

Saxagliptin
(CAS: 361442-04-8)

Saxagliptin is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is oral...

CAS 486460-32-6 Sitagliptin

Sitagliptin
(CAS: 486460-32-6)

Sitagliptin(MK 0431) is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.

CAS 150080-09-4 Talabostat mesylate

Talabostat mesylate
(CAS: 150080-09-4)

Talabostat mesylate is the orally bioavailable mesylate salt of an amino boronic dipeptide with antineoplastic and hematopoiesis- stimulating activities. By cle...

ASP-8497 free base
(CAS: 651055-25-3)

ASP-8497 free base is a long-acting and potent DPP-IV inhibitor. It improves glucose tolerance through glucose-dependent insulinotropic action via elevation of ...

CAS 906093-29-6 Teneligliptin hydrobromide

Teneligliptin hydrobromide
(CAS: 906093-29-6)

Teneligliptin hydrobromide is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor. It competitively inhibited human plasma, rat plasma, and human...

CAS 865759-25-7 Trelagliptin

Trelagliptin
(CAS: 865759-25-7)

Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with...

CAS 1186426-66-3 DBPR108

DBPR108
(CAS: 1186426-66-3)

DBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including ...

CAS 760937-92-6 Teneligliptin

Teneligliptin
(CAS: 760937-92-6)

Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor. It competitively inhibited human plasma, rat plasma, and human recombinant ...

CAS 654671-77-9 Sitagliptin phosphate monohydrate

Sitagliptin phosphate monohydrate
(CAS: 654671-77-9)

Sitagliptin phosphate is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts. It is used either alone or in combination with other oral anti...

CAS 274901-16-5 Vildagliptin

Vildagliptin
(CAS: 274901-16-5)

Glyptins are class of oral anti-hyperglycemic agents that inhibit dipeptidyl peptidase 4 (DPP-4), which can act as a serine exopeptidase. ASide from there use i...

CAS 868771-57-7 Melogliptin

Melogliptin
(CAS: 868771-57-7)

Melogliptin is a selective dipeptidyl peptidase IV (DPP-IV) inhibitor. But No development was reported about Phase-II for Type-2 diabetes mellitus.

CAS 1029877-94-8 Trelagliptin succinate

Trelagliptin succinate
(CAS: 1029877-94-8)

Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).

CAS 654671-78-0 Sitagliptin phosphate

Sitagliptin phosphate
(CAS: 654671-78-0)

Sitagliptin phosphate is a potent inhibitor of DPP4 in Caco-2 cell extracts.

CAS 869490-23-3 Gosogliptin

Gosogliptin
(CAS: 869490-23-3)

Gosogliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor. But no development was reported about Phase-II for Type-2 diabetes mellitus.

Reference Reading


1.Characterization of process-related impurities including forced degradation products of alogliptin benzoate and the development of the corres
Zhou Y1, Zhou W, Sun L, Zou Q, Wei P, OuYang P. J Sep Sci. 2014 Jun;37(11):1248-55. doi: 10.1002/jssc.201301384. Epub 2014 Apr 25.
The characterization of process-related impurities and forced degradants of alogliptin benzoate (Alb) in bulk drugs and a stability-indicating HPLC method for the separation and quantification of all the impurities were investigated. Alb was found to be unstable under acid and alkali stress conditions and two major degradation products (Imp-F and Imp-G) were observed. The optimum separation was achieved on Kromasil C18 (250 × 4.6 mm, 5 μm) using 0.1% perchloric acid (pH adjusted to 3.0 with triethylamine) and acetonitrile as a mobile phase in gradient mode. The proposed method was found to be stability indicating, precise, linear (0.10-75.0 μg/mL), accurate, sensitive, and robust for the quantitation of Alb and its process-related substances and degradation products. The structures of 11 impurities were characterized and confirmed by NMR spectroscopy, MS, and IR spectroscopy, and the most probable formation mechanisms of all impurities were proposed according to the synthesis route.
2.Alogliptin benzoate for the treatment of type 2 diabetes.
Seino Y1, Yabe D. Expert Opin Pharmacother. 2014 Apr;15(6):851-63. doi: 10.1517/14656566.2014.898750.
INTRODUCTION: Type 2 diabetes mellitus continues to be a global problem, placing an enormous burden on healthcare systems and resources. Effective treatment options to minimize the effects of hyperglycemia are essential. Most patients eventually need to take multiple drugs to maintain glycemic control, and many antidiabetic drugs are associated with adverse effects, such as hypoglycemia, weight gain or gastrointestinal effects. Dipeptidyl peptidase (DPP)-4 inhibitor is one of the newer classes of oral antidiabetic drug, and alogliptin is the most recently approved drug in this class.
3.Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice.
Yang D1, Nakajo Y, Iihara K, Kataoka H, Yanamoto H. Brain Res. 2013 Jun 23;1517:104-13. doi: 10.1016/j.brainres.2013.04.015. Epub 2013 Apr 17.
Effective interventions that provide obvious neuroprotection are currently fairly limited. Glucagon-like peptide-1 (GLP-1), an enhancer of insulin production with a trophic effect on β cells in the islets, has been found to be trophic for neuronal cells. Alogliptin benzoate (AGL), a selective inhibitor of dipeptidylpeptidase-4 (DPP-4) functioning as a long-acting agonist of GLP-1, is in clinical use worldwide for patients with diabetes mellitus type 2. To clarify whether administration of AGL, independent of the insulinotropic effect, protects the brain against focal ischemia, we investigated the effect of AGL on the development of cerebral infarction in non-diabetic normal mice. Male C57BL/6J mice were administered AGL (7.5, 15, or 30μg) once a day for three weeks by intragastric gavage. After the induction of temporary focal ischemia, volumes of infarcted lesions and neurological deficits were analyzed at 24h (acute phase) and seven days (chronic phase).
4.Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
Nakamura Y1, Inagaki M, Shimizu T, Fujita K, Inoue M, Gotoh H, Oguchi K, Goto Y. Nephron Clin Pract. 2013;123(1-2):46-51. doi: 10.1159/000351678. Epub 2013 Jun 11.
AIM: To evaluate the long-term efficacy of monotherapy with the dipeptidase-4 inhibitor alogliptin benzoate in hemodialysis (HD) patients with type 2 diabetes.